Download PDF
1 / Pages

Other users also viewed these articles

Prevalence of atherogenic dyslipidemia, related factors and level of lipid control in the general population of Galicia. GALIPEMIAS study Carlos Názara; Rosa M. Argüeso; Juan Pedro-Botet; Xavier Pintó; Jesús Millán; Marta Pena Seijo; Pablo A. Fernández; M. Eugenia Ameneiros; Alberto del Alamo; Avelino Rodríguez; José Antonio Díaz-Peromingo; María Rosa Vázquez Freire; Javier Muñiz; Teresa R. Pérez-Castro; José Luis Díaz-Díaz; Antonio Pose Reino;
Clin Investig Arterioscler. 2023;35:178-84
Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study Agustín Blanco Echevarría; Juan De Dios García Díaz; Assumpta Caixas; Núria Plana Gil; Miguel Ángel Rico Corral; Ian Bridges; Nafeesa Dhalwani; Sònia Gatell Menchen; Kausik K. Ray;
Clin Investig Arterioscler. 2023;35:263-71
Observational study of patients from a Lipid Unit on lipid-modifying therapy for primary and secondary prevention: ULFI Study Àlex Vila; Estel Pons; Patricia Trinidad García; Daniel Vidal; Sara López; Armand Grau;
Clin Investig Arterioscler. 2023;35:272-9